What is NBSE's current stock price?

NBSE (NeuBase Therapeutics, Inc.) is currently trading at $0.38 with a market cap of $1.4M.

What sector is NeuBase Therapeutics, Inc. in?

NeuBase Therapeutics, Inc. (NBSE) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

Back to Market返回行情

NBSE NeuBase Therapeutics, Inc.

NASDAQHealthcare

$0.3780-1.56%ClosedMarket Cap: $1.4M

As of 2024-05-10 16:00

Why NBSE matters now

NeuBase Therapeutics, Inc. (NBSE) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.38 with -1.56% on the session and $1.4M in market capitalization.

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

NASDAQ

Beta

0.94

Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.